Mitochondrial activation miRNA and application of mitochondrial activation miRNA-loaded radix puerariae exosome in targeting resistance to Parkinson's

Kudzu root exosomes loaded with miRNA and modified with neuron-targeting ligands address the inefficiencies of current miRNA delivery systems by specifically targeting pathological neurons, enhancing mitochondrial autophagy and restoring mitochondrial function to treat Parkinson's disease.

CN119055672AActive Publication Date: 2024-12-03ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411099980.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-12-03
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

Current miRNA drug delivery systems for treating Parkinson's disease face challenges such as inefficiency, immune responses, and instability, making it difficult to effectively target and restore mitochondrial function.

Method used

The use of kudzu root exosomes loaded with miRNA, modified with neuron-targeting ligands, to deliver miRNA specifically to pathological neurons, promoting mitochondrial autophagy and improving mitochondrial dysfunction.

Benefits of technology

The miRNA-loaded kudzu root exosomes enhance mitochondrial autophagy, reduce oxidative stress, and improve ATP generation, effectively targeting and restoring mitochondrial function in pathological neurons, thereby alleviating Parkinson's disease symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055672A_ABST
    Figure CN119055672A_ABST
Patent Text Reader

Abstract

The invention discloses application of mitochondrial activation miRNA and loaded radix puerariae exosome targeting resistance of the mitochondrial activation miRNA, and belongs to the field of biological application. The miRNA provided by the invention comprises at least one of miRNAs of which the sequences are as shown in SEQ ID No, 1 to SEQ ID No, 23. The radix puerariae exosome and miRNA delivered by the radix puerariae exosome show a good treatment effect on Parkinson's disease, and the radix puerariae exosome and miRNA mainly play a role in improving mitochondrial dysfunction, such as promoting mitochondrial autophagy, improving mitochondrial membrane potential, reducing oxidative stress, maintaining completeness of mitochondrial inner membrane respiratory chain complex and increasing ATP (adenosine triphosphate) generation. The invention further discloses a delivery scheme adopting the exosome which is targeted and modified by neurons and is derived from radix puerariae as the miRNA carrier, the targeting property and the stability of miRNA can be improved, and the problems that miRNA drugs are low in delivery efficiency and easy to degrade are solved. According to the invention, the treatment process of Parkinson's disease is expected to be promoted through the neuron-targeted kudzu vine root exosome and the miRNA delivered by the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biological applications, and in particular relates to the application of mitochondrial activated miRNA and kudzu root exosomes loaded with the miRNA in targeted anti-Parkinson's disease treatment. Background Art

[0002] An important pathogenic mechanism of Parkinson's disease involves cell damage caused by mitochondrial dysfunction. Mitochondrial dysfunction can affect cell function in many aspects, including energy production, oxidative stress, metabolic regulation, and cell apoptosis. Mitochondria are mainly responsible for energy production in cells, and impaired function can lead to reduced production of adenosine triphosphate (ATP), causing energy production disorders. In addition, when mitochondrial function is impaired, the mitochondrial membrane potential decreases and free radical production increases, which can damage intracellular lipids, proteins, and DNA. Mitochondria are involved in the metabolic pathways of multiple substances, and metabolic disorders caused by their disorders can impair lipid and carbohydrate metabolism. Mitochondrial dysfunction can also lead to impaired apoptosis signal transduction, apoptosis factor release, and apoptosis-related protein expression, promoting cell apoptosis.

[0003] MiRNA (microRNA) is a cutting-edge strategy for treating mitochondrial dysfunction, aiming to restore mitochondrial function by regulating gene expression. MiRNA is a class of small non-coding RNA molecules that regulate a variety of biological processes in cells by binding to the mRNA of the target gene, inhibiting its translation or promoting its degradation. In the treatment of mitochondrial dysfunction, miRNA can target key genes related to mitochondrial function, thereby regulating mitochondrial biogenesis, improving oxidative stress levels, or alleviating mitochondrial-related apoptosis. Through these mechanisms, miRNA is expected to improve the symptoms of Parkinson's disease and delay its progression.

[0004] Regulating the expression of mitochondrial autophagy-related genes through miRNA to promote mitochondrial autophagy and thus ensure the normal function of mitochondria is a potential entry point for the effective treatment of Parkinson's disease. Mitochondrial autophagy plays an important role in improving mitochondrial dysfunction by cleaning up damaged mitochondria, reducing oxidative stress, and promoting mitochondrial renewal. Mitochondrial autophagy can remove damaged mitochondria that produce too many free radicals and cause oxidative stress, thereby reducing the harmful effects on cells. In addition, mitochondrial autophagy helps to restore mitochondrial function by clearing old mitochondria and promoting the generation of new mitochondria, maintaining a healthy balance of mitochondria in cells. This process can also reduce the apoptotic factors released by mitochondria, thereby protecting cells from unnecessary programmed death.

[0005] However, miRNA drug development faces many difficulties. At present, the effective delivery of miRNA drugs is still difficult, and traditional delivery methods may be inefficient or induce immune responses, so new delivery systems need to be developed. In addition, miRNA is easily degraded in the body, so improving its stability and extending its half-life are key, which requires optimizing chemical modifications or delivery strategies. Finally, the difficulty in developing gene-specific miRNA drugs also limits their clinical application and commercialization.

[0006] Exosomes are a type of extracellular vesicles with a diameter of about 30-150 nanometers. They can carry various biomolecules, including miRNA, and have been shown to have potential application value in the treatment of various diseases through the miRNA contained in them, which provides significant help for the development of miRNA drugs. Exosomes have natural biocompatibility, and as cell-derived nanovesicles, they show efficient cellular internalization properties, ensuring the intracellular delivery of miRNA. In addition, the miRNA inside exosomes is relatively stable and not easily degraded by enzymes in the body, thereby extending its half-life. Specific ligands or antibodies can also be loaded on the surface of exosomes to enhance the targeting specificity to specific cells or tissues. As a natural miRNA reservoir, the application of exosomes is expected to solve some challenges in traditional miRNA drug delivery systems, and provide a rich miRNA screening library for disease treatment to increase the possibility of discovering effective miRNA molecules and promote the development of miRNA drugs.

[0007] At present, there are few reports on therapeutic miRNAs for Parkinson's disease. The discovery and targeted verification of such miRNAs are expected to promote the treatment of Parkinson's disease. Summary of the invention

[0008] In order to solve the problems in the prior art, the present invention proposes the application of mitochondrial activated miRNA and its loaded kudzu root exosomes for targeted anti-Parkinson's disease. The present invention also explains that improving mitochondrial dysfunction is one of its main anti-PD mechanisms.

[0009] In a first aspect, the present invention first provides the use of miRNA in the preparation of a drug for treating Parkinson's disease, wherein the miRNA comprises at least one of the miRNAs with sequences shown in SEQ ID No. 1 to SEQ ID No. 23.

[0010] Furthermore, the miRNA uses exosomes as carriers, and the miRNA is encapsulated inside the exosomes.

[0011] Furthermore, the exosomes or the exosomes encapsulating the miRNA are extracts derived from Pueraria lobata.

[0012] Preferably, the extract is derived from a pulp prepared from Pueraria root, and the pulp is one or more of freshly squeezed liquid, leaching liquid, and decoction liquid.

[0013] Furthermore, the extract is derived from one or more of fresh Pueraria leaves, Pueraria flowers, Pueraria roots, Pueraria vines, Pueraria stems, Pueraria processed products, and Pueraria decoctions.

[0014] Furthermore, the exosomes or the exosomes encapsulating the miRNA are functional exosomes with neuron-targeting ligands modified on the surface, so as to improve the ability of the pueraria exosomes and the miRNA delivered by them to be specifically taken up by pathological neurons in the present invention, thereby increasing the therapeutic effect on Parkinson's disease.

[0015] Furthermore, the targeting ligand is at least one of a small molecule, a polypeptide, an antibody, and a lipid.

[0016] Preferably, the neuron targeting ligand is fixed on the surface of Pueraria exosomes by chemical coupling or physical adsorption to achieve specific targeting of dopaminergic neurons.

[0017] Preferably, the small molecule is a ligand capable of targeting dopamine receptors, which is an artificially synthesized selective D1-like or D2-like receptor agonist and antagonist, as well as a natural product, such as one or more of dopamine, levodopamine, benzyltetrahydroisoquinoline alkaloids, aporphine alkaloids, calcitonin alkaloids, phenanthrene alkaloids, berberine and tetrahydroprotoberberine, and ergot alkaloids; the polypeptide is one or more of transferrin, low-density lipoprotein, insulin, leptin, RVG29, c(RGDyk), c(RGDfk), Angiopep-2, THR, CRT, g7, TGN, TAT, SynB1, RDP, KC2S, LCDX, DCDX, MiniAp-4, and G23; the protein is one or more of an anti-dopamine receptor antibody, an anti-dopamine transporter antibody, a neuroadhesion protein, and a calcineurin; the lipid is one or more of cerebrophospholipids, ceramides, sphingolipids, and glycolipids.

[0018] In a second aspect, the present invention provides a drug for treating Parkinson's disease, characterized in that the drug contains miRNA, and the miRNA contains at least one of the miRNAs with sequences shown in SEQ ID No.1 to SEQ ID No.23.

[0019] In a third aspect, the present invention provides a drug for treating Parkinson's disease, characterized in that the drug comprises exosomes derived from Pueraria lobata, wherein miRNA is encapsulated inside the exosomes, and the miRNA comprises at least one of the miRNAs whose sequences are shown in SEQ ID No.1 to SEQ ID No.23.

[0020] Furthermore, the exosomes are functional exosomes with neuron-targeting ligands modified on their surfaces.

[0021] According to a preferred embodiment of the present invention, the miRNA provided in the above aspects is preferably at least one of the miRNAs with sequences such as SEQ ID No.1, SEQ ID No.2, SEQ ID No.4, SEQ ID No.5, SEQ ID No.12, SEQ ID No.16, SEQ ID No.19, SEQ ID No.20, SEQ ID No.21, SEQ ID No.22, and SEQ ID No.23.

[0022] The benefit of the present invention lies in that the miRNA and the drug for treating Parkinson's disease described in the present invention can improve mitochondrial dysfunction, including promoting mitochondrial autophagy, improving mitochondrial membrane potential, reducing oxidative stress, maintaining the integrity of the mitochondrial inner membrane respiratory chain complex, and increasing ATP generation. Further, the mitochondrial autophagy is PINK1-PARKIN-mediated mitochondrial autophagy; the mitochondrial inner membrane respiratory chain complex is one or more of complexes I, II, III, IV, and V.

[0023] The miRNA and the drug for treating Parkinson's disease of the present invention improve the key genes involved in mitochondrial dysfunction: the miRNA improves mitochondrial dysfunction by reducing the expression of LRRK2, USP8, and USP15 in cells and increasing the expression of TOMM7, PINK1, SQSTM1, NDUFB4, and ATP5J2.

[0024] The miRNA and the drug for treating Parkinson's disease described in the present invention can improve mitochondrial dysfunction by increasing the content of one or more of the above endogenous miRNAs in cells, specifically including promoting mitochondrial autophagy, increasing mitochondrial membrane potential, reducing oxidative stress, maintaining the integrity of the mitochondrial inner membrane respiratory chain complex, and increasing one or more of ATP generation.

[0025] The miRNA and the drug for treating Parkinson's disease described in the present invention can reduce the expression of LRRK2, USP8, and USP15 in cells, and increase the expression of TOMM7, PINK1, SQSTM1, NDUFB4, and ATP5J2 by ​​increasing the content of one or more of the above endogenous miRNAs in cells, thereby promoting PINK1-PARKIN-mediated mitochondrial autophagy to clear damaged mitochondria and alleviate the cascade events of cell damage patterns caused by them, and ensure the integrity of the structure of the respiratory chain complexes I and V of the mitochondrial inner membrane to improve energy supply.

[0026] The neuron-targeted kudzu root exosomes provided by the present invention and the miRNA delivered thereto have great potential in the treatment of Parkinson's disease, and can specifically target neurons and widely regulate the mitochondrial dysfunction of pathological neurons. In addition, the miRNA upregulator based on kudzu root exosomes in the present invention has good safety and basically no toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 is the particle size of the kudzu root exosomes obtained in Example 1;

[0028] Figure 2 This is a transmission electron micrograph of the kudzu root exosomes obtained in Example 1;

[0029] Figure 3 The transmission electron microscopy images of the kudzu root exosomes obtained in Example 1 after storage for different time periods;

[0030] Figure 4 is the particle size of the neuron-targeted Pueraria exosomes obtained in Example 2;

[0031] Figure 5 This is a transmission electron microscopy image of the neuron-targeted kudzu root exosomes obtained in Example 2;

[0032] Figure 6 The uptake effect evaluation of the pueraria exosomes before and after targeted modification in the neuronal model cells SH-SY5Y in Example 3;

[0033] Figure 7 The intersection of miRNAs contained in the kudzu root exosomes in Example 4 and the differentially upregulated miRNAs in SH-SY5Y cells treated with kudzu root exosomes;

[0034] Figure 8 , 9 This is the KEGG and GO enrichment analysis diagram of the pathological Parkinson's model cell SH-SY5Y before and after being treated with Pueraria exosomes in Example 5;

[0035] Fig.10The effect of the miRNA delivered by the pueraria exosomes in Example 6 on the activity of pathological Parkinson's model cells SH-SY5Y;

[0036] Fig.11 The effect of the miRNA delivered by the kudzu root exosomes in Example 7 on the mitochondrial membrane potential of the pathological Parkinson's model cell SH-SY5Y;

[0037] Fig.12 The effect of the miRNA delivered by the kudzu root exosomes in Example 8 on the ATP content in the pathological Parkinson's model cells SH-SY5Y;

[0038] Figure 13-15 To illustrate the targeted regulatory effect of miRNA delivered by Pueraria exosomes on LRRK2, USP8, and USP15 in Example 9;

[0039] Fig.16 The pueraria exosomes in Example 10 promote mitochondrial autophagy and improve mitochondrial morphology in pathological Parkinson's model cells SH-SY5Y;

[0040] Fig.17 The improvement of Pueraria exosomes on the activities of mitochondrial respiratory chain complexes I and V in pathological Parkinson's model cells SH-SY5Y in Example 11;

[0041] Fig.18 , 19 The expression of LRRK2, TOMM7, PINK1, SQSTM1, NDUFB4, and ATP5J2 in the pathological Parkinson's model cells SH-SY5Y after treatment with Pueraria exosomes in Example 12;

[0042] Fig. 20 The movement trajectory of the Parkinson's model mice in Example 13 in the open field after treatment with Pueraria exosomes before and after targeted modification;

[0043] Fig.21 The rotarod performance of Parkinson's model mice after treatment with Pueraria exosomes before and after targeted modification in Example 14;

[0044] Fig. 22 The tail suspension performance of Parkinson's model mice after treatment with Pueraria exosomes before and after targeted modification in Example 15;

[0045] Fig.23 The expression of tyrosine hydroxylase in substantia nigra dopaminergic neurons in Parkinson's model mice after treatment with Pueraria exosomes before and after targeted modification in Example 16;

[0046] Fig.24The expression of Nissl's substance in substantia nigra dopaminergic neurons in Parkinson's model mice after treatment with Pueraria exosomes before and after targeted modification in Example 17;

[0047] Fig.25 , 26 In vivo molecular verification of the improvement of mitochondrial dysfunction by Pueraria exosomes before and after targeted modification in Example 18;

[0048] Fig. 27 This is the biosafety evaluation of Pueraria exosomes before and after targeted modification in Example 19. DETAILED DESCRIPTION

[0049] The present invention is further described and illustrated below in conjunction with specific embodiments. The embodiments are merely exemplary of the present disclosure and do not define the scope of limitation. The technical features of each embodiment of the present invention may be combined accordingly without conflicting with each other.

[0050] Example 1 Preparation and characterization of kudzu root exosomes

[0051] Take 50g of fresh Pueraria root, wash off the residual soil, and extract the juice in a juicer with 150mL phosphate buffer. After filtering with a strainer to remove the residue, the collected juice was centrifuged at 4℃1000×g for 10min, 4000×g for 40min, and 10000×g for 60min to remove large particles and cell debris. After the supernatant was centrifuged at 4℃150000×g for 90min, the bottom precipitate was resuspended with an appropriate amount of PBS, and after sucrose density gradient centrifugation (6%, 30%, 45%, 60%) at 4℃150000×g for 90min, the 30% and 45% layers were combined, and Pueraria exosomes were obtained after ultracentrifugation and washing. The particle size of Pueraria exosomes was measured using a Malvern particle size analyzer, the morphology of exosomes was photographed using a transmission electron microscope, and the protein concentration of exosomes was quantified using a BCA kit. The morphology of Pueraria exosomes after storage for different times was observed. As shown in the attached Figure 1 As shown in the attached figure, the particle size of the obtained pueraria exosomes is about 125nm, and the dispersion performance is good. Figure 2 As shown in Figure 2, Pueraria exosomes show a teacup-shaped structure under transmission electron microscopy, which is consistent with the classic characteristics of exosomes. The white area on the periphery is the lipid bilayer, which provides good protection for the miRNA encapsulated inside. Figure 3 As shown, after storage for about 30, 90, and 360 days, the morphology of Pueraria exosomes did not change significantly, indicating their good stability.

[0052] Example 2 Preparation and characterization of neuron-targeted kudzu root exosomes

[0053] The kudzu root exosomes were co-incubated with DSPE-PEG2000-RVG29 at 37°C and a mass ratio of 1:1 for 0.5 h. After the incubation, the free DSPE-PEG2000-RVG29 was removed by centrifugation at 4°C and 150,000 × g for 60 min, and the bottom precipitate was resuspended to obtain neuron-targeted kudzu root exosomes. The particle size and potential of the exosomes were measured using a Malvern particle size analyzer, and the morphology of the exosomes was photographed using a transmission electron microscope. As shown in the attached figure Figure 4 , 5 As shown in the figure, the morphology of the neuron-targeted kudzu root exosomes did not change significantly, indicating the feasibility of the modification method. Due to the introduction of functional side chains, the particle size increased slightly to about 133 nm.

[0054] Example 3 Evaluation of the uptake effect of Pueraria exosomes before and after targeted modification in neuronal model cells SH-SY5Y

[0055] The pueraria exosomes and neuron-targeted pueraria exosomes were labeled with the fluorescent dye DiO, and the cells were collected after incubation with SH-SY5Y cells for different time periods. The fluorescence-positive SH-SY5Y cells were analyzed using flow cytometry combined with CytExpert 2.4 software to analyze the uptake efficiency at different time points. Figure 6 As shown in the figure, at the 2h time point, the number of fluorescent positive cells reached nearly 50%, and the maximum uptake percentage was almost reached at 4h, which indicates that the cells have excellent uptake performance for kudzu exosomes. Moreover, at different time points, the uptake rate of RVG-modified neuron-targeted kudzu exosomes was higher than that of pure kudzu exosomes, indicating optimized uptake performance.

[0056] Example 4 Intersection analysis of kudzu root exosomes and differentially upregulated miRNAs in SH-SY5Y cells after kudzu root exosome treatment

[0057] The miRNAs in pueraria exosomes and SH-SY5Y cells before and after pueraria exosome treatment were extracted using RNA extraction kits, and the detailed expression profiles and relative abundances of miRNAs were obtained by high-throughput sequencing. The differentially upregulated miRNAs in SH-SY5Y cells after pueraria exosome treatment were intersected with the miRNAs in pueraria exosomes. Figure 7As shown, there are 23 intersecting miRNAs, indicating that Pueraria exosomes deliver 23 miRNAs to SH-SY5Y cells, which are the basis for their efficacy. After analysis, these 23 miRNAs are recorded in the miRBase database, and their names are hsa-miR-27a-3p, hsa-miR-148a-3p, hsa-miR-194-5p, hsa-miR-185-5p, hsa-miR-15a-5p, hsa-miR-30a-5p, hsa-let-7i-5p, hsa-let-7e-5p, hsa-miR-20a-5p, hsa-let-7c-5p, hsa-let-7a -5p, hsa-miR-30e-5p, hsa-miR-22-3p, hsa-miR-199b-3p, hsa-let-7d-5p, hsa-miR-30b-5p, hsa-miR-450a-5p, hsa-miR-15b-5p, hsa-miR-26b-5p, hsa-let-7g-5p, hsa-let-7f-5p, hsa-miR-16-5p, hsa-miR-374b-5p, and their corresponding sequences are shown in SEQ ID No.1 to SEQ ID No.23 and in Table 1. The miR-NO in the rightmost column of Table 1 is the abbreviation of each sequence in the accompanying drawing.

[0058] Table 1: Names and sequences of MiRNAs (SEQ ID No. 1 to SEQ ID No. 23)

[0059]

[0060]

[0061] According to common sense in the art, these miRNA sequences can be extracted from Pueraria root as described in the examples of this application, or they can be artificially synthesized. It should be understood that miRNAs of the same sequence from different sources should have the same or nearly the same activity when preparing the same drug for disease treatment. Therefore, the present invention does not limit the source of miRNA. Without loss of generality, the subsequent examples still use miRNAs delivered by exosomes from Pueraria root to evaluate miRNA-related properties, but its properties should be understood to be equally applicable to miRNAs of the same sequence from other sources.

[0062] Example 5 KEGG and GO enrichment analysis of differentially expressed genes in pathological SH-SY5Y cells before and after treatment with Pueraria exosomes

[0063] KEGG and GO enrichment analysis were used to cluster differentially expressed genes. KEGG enrichment analysis tools were used to enrich specific metabolic pathways or signal transduction pathways. GO enrichment analysis tools were used to enrich one or more of the biological processes, molecular functions, or cellular components. Figure 8 , 9 As shown, the results of KEGG and GO enrichment analysis showed a wide range of events related to autophagy (mitophagy) and mitochondrial structure, indicating the potential regulatory role of miRNAs delivered by Pueraria exosomes on mitochondrial dysfunction.

[0064] Example 6 Effect of miRNA delivered by Pueraria exosomes on the activity of neuronal pathological Parkinson's model cells SH-SY5Y

[0065] 5000 SH-SY5Y cells were inoculated into each well of a 96-well plate. After overnight attachment, the cell culture medium was removed. 1mM MPP+ was applied to SH-SY5Y cells for 24h to establish an in vitro Parkinson's disease pathological cell model. After modeling, a blank group and 1mM MPP+ were set up. + Model group, 1mM MPP + / miRNA transfection group. The model group was replaced with normal culture medium after modeling, and the transfection group was transfected with the corresponding miRNA into SH-SY5Y according to the operating instructions of Thermo Fisher's lipo3000 transfection reagent, with 5 replicates in each group. After 24 hours, the cell culture medium was removed and replaced with serum-free medium containing MTT, and incubated for another 4 hours. After that, 100 μL Formazan solution was added to each well, mixed appropriately, and shaken in the dark for 10 minutes. After the purple crystals were completely dissolved, the absorbance was measured at 570 nm. As shown in the attached Fig.10 As shown, taking the model group as a benchmark, different miRNAs showed different abilities to improve the survival of PD pathological cell models.

[0066] Example 7 Effect of miRNA delivered by Pueraria exosomes on mitochondrial membrane potential of neuronal pathological Parkinson's model cells SH-SY5Y

[0067] 200,000 SH-SY5Y cells were inoculated into each well of a 6-well plate. After overnight attachment, the cell culture medium was removed. A blank group was set up with 1 mM MPP. + Model group, 1mM MPP + / miRNA transfection group. According to the operating instructions of the mitochondrial membrane potential detection kit (BL711A, Biosharp), add 1 mL of JC-1 staining working solution to each well, mix thoroughly, and incubate at 37°C in a cell culture incubator for 20 minutes. After the incubation, remove the supernatant and wash twice with JC-1 staining buffer (1×). Use a fluorescence microplate reader to measure the fluorescence intensity values ​​at wavelengths of 490nm and 525nm, and calculate the ratio of red and green fluorescence intensities. As shown in the attached Fig.11 As shown, taking the model group as a benchmark, different miRNAs showed different abilities to improve the mitochondrial membrane potential of the PD pathological cell model.

[0068] Example 8 Effect of miRNA delivered by Pueraria exosomes on ATP content in neuronal pathological Parkinson's model cells SH-SY5Y

[0069] 200,000 cells were seeded into each well of a 6-well plate. After overnight attachment, the cell culture medium was removed. A blank group was set up with 1mM MPP + Model group, 1mM MPP + / miRNA transfection group. According to the operating instructions of the ATP detection kit (S0026, Biotech), add 200μL of lysis buffer to lyse the cells, and use a pipette to repeatedly blow to allow the lysis buffer to fully contact and lyse the cells. After lysis, centrifuge at 4℃12000g for 5 minutes and take the supernatant. Dilute the ATP standard solution with ATP detection lysis buffer to a concentration gradient of 0.01, 0.03, 0.1, 0.3, 1, 3 and 10μM to prepare an ATP standard concentration and RLU value curve. Add 100μL of ATP detection working solution to the detection well and leave it at room temperature for 3-5 minutes to consume all the background ATP. Then add 20μL of sample or standard to the detection well, and determine the RLU value using a chemiluminometer. As shown in the attached Fig.12 As shown, taking the model group as a benchmark, different miRNAs showed different abilities to improve ATP production in PD pathological cell models.

[0070] Example 9 Evaluation of the targeting effect of kudzu root exosomes delivering miRNA on key genes of mitochondrial autophagy

[0071] TargetScan (https: / / www.targetscan.org / vert_80 / ) was used to predict the miRNA target sequence sites and the 3′UTR sequences of LRRK2, USP8, and USP15. Based on the 3′UTR sequences (Wide type, WT) of LRRK2, USP8, and USP15 in NCBI (National Center for Biotechnology Information), as well as the mutant 3′UTR sequences (Mutant type, MUT) of the predicted target sequences, primers were designed (Sangon, China), and the full-length sequences and sequences containing SacI and XhoI restriction sites were amplified by PCR, and the PCR products were inserted into the firefly / rabbit luciferase reporter vector PmirGLO (Fenghe bio, China) between the SacI and XhoI restriction sites (Takara, Japan). Then, the recombinant plasmids were screened with ampicillin (Aladdin, China) to successfully construct strains, and the strains were verified by DNA sequencing (Sangon, China). SH-SY5Y cells were seeded in 12-well plates at 200,000 per well. After 16 h, blank plasmid PmirGLO, reporter gene type Pmi-3'UTR WT or Pmi-3'UTR MUT (1 μg / well) and miRNA (negative control, NC mimic or miRNA mimic) (30 ng / well) were co-transfected into SH-SY5Y. Blank PmirGLO and miRNA NC model were used as controls. After 48 h of transfection, the luciferase activities of firefly and renilla were continuously measured using a dual luciferase reporter gene assay kit (YEASEN, China) to identify the binding of the target gene to miRNA. For each individual analysis, the Renilla luciferase signal was normalized to the firefly luciferase signal. As shown in the attached Figure 13-15 As shown, after miRNA binds to the target gene, the normalized firefly luciferase signal decreases, indicating the direct regulatory effect of miRNA on the key genes LPPK2, USP8, and USP15 that regulate mitochondrial dysfunction.

[0072] Example 10 Effects of Pueraria exosomes on mitochondrial autophagy and mitochondrial morphology in neuronal pathological Parkinson's model cells SH-SY5Y

[0073] The cells were fixed in 2.5% glutaraldehyde solution at 4°C overnight and rinsed with PBS. The samples were fixed with 1% osmium acid solution for 1-2 hours and rinsed three times with PBS. Dehydrated with gradient concentrations of ethanol solution (30%, 50%, 70%, 80%) for 15 minutes respectively, and then transitioned to 90% and 95% acetone solutions for 15 minutes each. Finally, the samples were treated with pure acetone twice, each for 20 minutes, treated with a mixture of Spurr embedding agent and acetone (V / V=1 / 1) for 1 hour, treated with a mixture of Spurr embedding agent and acetone (V / V=3 / 1) for 3 hours, and treated with pure embedding agent overnight. The infiltrated samples were embedded and heated at 70°C overnight to obtain encapsulated samples. The samples were sliced ​​in an ultramicrotome (LEICA EMUC7) to obtain 70-90nm slices. Stain with lead citrate solution and 50% ethanol saturated solution of uranyl acetate peroxide for 5-10 minutes and observe under a transmission electron microscope (Hitachi H-7650). Fig.16 As shown, compared with the model group cells, obvious mitophagy structures can be observed after treatment with Pueraria exosomes, and the morphology of mitochondrial cristae is more complete, which indicates that Pueraria exosomes can clear damaged mitochondria by promoting mitophagy and maintain the integrity of the mitochondrial inner membrane respiratory chain complex.

[0074] Example 11 Effects of Pueraria exosomes on the activities of mitochondrial respiratory chain complexes I and V in neuronal pathological Parkinson's model cells SH-SY5Y

[0075] The activities of mitochondrial complex I and V were detected using CheKineTM MRC Complex I Activity Assay Kit (KTB1850) and CheKineTM MRC V Activity Assay Kit (KTB1890). Fig.17 As shown, compared with the model group, the activities of mitochondrial respiratory chain complexes I and V in pathological neurons were improved after treatment with Pueraria exosomes.

[0076] Example 12 Molecular verification of the improvement of pueraria exosomes on mitochondrial dysfunction in neuronal pathological Parkinson's model cells SH-SY5Y

[0077] The total protein of the model group cells and exosome-treated cells was extracted using RIPA lysis buffer, and then the total protein was quantified using a BCA quantitative kit. 8-12% separation gel and 5% concentrated gel were prepared, 60 μg of total protein was loaded in each well, 10-15 μl per well, 60V for concentrated gel and 80V for separation gel for about 2 hours. The PVDF membrane was soaked in methanol for 20 seconds, then transferred to Tris-Glycine transfer buffer (containing 5% methanol) for at least 5 minutes; the SDS-PAGE gel was balanced in Tris-Glycine transfer buffer for at least 30 minutes; the membrane was fully wet transferred at 100V constant voltage under cooling conditions for 2 hours. The primary antibody was dissolved in T-TBS at a certain ratio and incubated at 4°C overnight; then rinsed with T-TBS for 5 minutes × 4. The secondary antibody was dissolved in T-TBS at a certain ratio, room temperature for 1 hour,; then rinsed with T-TBS for 5 minutes × 5. West Dura Extended Duration Substrate was used and the instructions were followed to prepare about 1 ml of ECL working solution. The transfer membrane was incubated at room temperature for 1 min, and then the excess ECL reagent was removed. The membrane was sealed with plastic wrap, and X-ray film was placed in a dark box for exposure for 5-10 min before development and fixing. The optical density values ​​of the bands were analyzed using Image J 1.8.0 image processing software (USA). Each band was repeated 3 times. The relative expression of the target protein was expressed as {target protein (optical density value) / internal reference (optical density value)}×10n. The results were expressed as mean ± standard deviation. As shown in the attached Fig.18 , 19 As shown, compared with the model group and the Pueraria exosome treatment group, there were obvious grayscale differences in the protein blots of LRRK2, TOMM7, PINK1, SQSTM1, ATP5J2, and NDUFB4, indicating that Pueraria exosomes improved mitochondrial dysfunction through the mitophagy pathway and maintaining the integrity of the mitochondrial inner membrane respiratory chain complex.

[0078] Example 13 Open field test

[0079] The mice were divided into a blank group, a Parkinson's model group (no drug intervention), a Pueraria exosome treatment group, and a RVG-modified neuron-targeted Pueraria exosome treatment group. The Parkinson's model was constructed by intraperitoneal injection of MPTP into mice for seven consecutive days. After the treatment course, the mice in each group were placed in a 45×45 cm 2 The mice were placed in a box with an infrared light wave activity monitor on top to record the movement of the mice within 5 minutes. The detection area was cleaned with 75% ethanol after each test to eliminate the influence of odor. Fig. 20As shown, compared with the Parkinson's model group, the distance moved by mice in the Pueraria exosome treatment group in the open field increased and the trajectory was more complex, indicating that the mice's autonomous movement ability was improved, and the RVG-modified neuron-targeted Pueraria exosome treatment effect was the most significant.

[0080] Example 14 Rotarod experiment

[0081] The coordination of mice was measured using an accelerating rotarod apparatus and mice in the blank group, Parkinson's model group (no drug intervention), Pueraria exosome treatment group, and RVG-modified neuron-targeted Pueraria exosome treatment group were trained before the formal experiment. One day before the experiment, mice were trained on a rotating rod that accelerated from 0 rpm to 40 rpm in 240 s. The formal experiment was carried out on the second day to measure the time the mice stayed on the rod and the rotation speed when they fell. As shown in the attached Fig.21 As shown, compared with the Parkinson's model group, the mice in the Pueraria exosome treatment group continued to move on the rotarod for a longer time, indicating that the coordination of the mice's movements was improved, and the RVG-modified neuron-targeted Pueraria exosome treatment effect was the most significant.

[0082] Example 15 Tail suspension experiment

[0083] Depressive-like behavior was assessed using the tail suspension test. Mice in the control group, Parkinson's model group (no drug intervention), Pueraria exosome treatment group, and RVG-modified neuron-targeted Pueraria exosome treatment group were suspended from a node approximately 1.5 inches from the base of the tail for 10 minutes. The immobility time of the mice within 6 minutes after the assessment was performed. Fig. 22 As shown, compared with the Parkinson's model group, the immobility time of mice in the Pueraria exosome treatment group during tail suspension was reduced, indicating the improvement of the depressive behavior of mice, and the RVG-modified neuron-targeted Pueraria exosome treatment effect was the most significant.

[0084] Example 16 Tyrosine Hydroxylase Immunohistochemical Staining

[0085] The brain tissues of mice in the blank group, Parkinson's model group (without drug intervention), Pueraria exosome treatment group, and RVG-modified neuron-targeted Pueraria exosome treatment group were collected, fixed, dehydrated, sliced, and embedded in paraffin. The serum was blocked at room temperature for 30 minutes. After the primary antibody and secondary antibody were added dropwise, DAB was added for color development. The cell nuclei were counterstained, and the sections were dehydrated and sealed for examination under a microscope and images were collected. Hematoxylin stained the cell nuclei in blue, and DAB showed positive expression in brown-yellow. The grayscale value of the positive area was analyzed. As shown in the attached figure Fig.23 As shown, compared with the Parkinson's model group, the brown-yellow color and larger area of ​​DA-positive areas in the substantia nigra of mice in the Pueraria exosome treatment group indicated a higher expression level of tyrosine hydroxylase, and the RVG-modified neuron-targeted Pueraria exosome treatment had the most significant effect.

[0086] Example 17 Nissl staining

[0087] The brain tissues of mice in the blank group, Parkinson's model group (without drug intervention), Pueraria exosome treatment group, and RVG-modified neuron-targeted Pueraria exosome treatment group were collected, fixed, dehydrated, sliced, and paraffin-embedded. The slices were dewaxed to water and washed three times with pure water. The slices were stained with Nissl body staining solution for 5 minutes. Washed with pure water three times. Dehydrated quickly with anhydrous ethanol, made transparent with xylene, and sealed with neutral gum. The Nissl bodies in neurons appeared as dark blue particles, the nuclei were light blue, and the background was light blue. As shown in the attached Fig.24 As shown, compared with the Parkinson's model group, the area of ​​Nissl body-positive regions in the Pueraria exosome-treated mice was significantly increased, and the RVG-modified neuron-targeted Pueraria exosome treatment effect was the most significant.

[0088] Example 18 Verification of the in vivo mechanism of kudzu root exosomes in improving mitochondrial dysfunction

[0089] The substantia nigra of the brain tissue of mice in the blank group, model group, kudzu root exosome treatment group, and RVG modified kudzu root exosome treatment group were sampled. The tissue was homogenized using a tissue grinder, and the total protein was extracted. The same as in Example 12. Fig.25 , 26 As shown, compared with the model group, there were obvious grayscale differences in the protein blots of LRRK2, TOMM7, PINK1, SQSTM1, ATP5J2, and NDUFB4 in the Pueraria exosome treatment group, and the expression levels of the corresponding genes in the RVG-modified Pueraria exosome treatment group were lower or higher, indicating that Pueraria exosomes improved mitochondrial dysfunction through the mitophagy pathway and maintaining the integrity of the mitochondrial inner membrane respiratory chain complex.

[0090] Example 19 H&E staining

[0091] After dewaxing, wash the sections and then add hematoxylin for staining for 5 minutes. Subsequently, briefly expose the sections to a hydrochloric acid aqueous solution for 2 seconds, followed by differentiation using an ammonia solution for 15-30 seconds. Then wash the sections to remove any excess staining reagent. Next, dehydrate the sections using 95% alcohol and then stain with an eosin solution for 5-8 seconds. After dehydration and sealing, observe the stained sections. Fig. 27 As shown, no obvious organ damage was caused before and after targeted modification of Pueraria exosomes, indicating its good biosafety.

[0092] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the present invention. For ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. Use of miRNA in the preparation of a drug for treating Parkinson's disease, wherein the miRNA comprises at least one of the miRNAs with sequences as shown in SEQ ID No. 1 to SEQ ID No.

23.

2. The use according to claim 1, characterized in that: The miRNA is at least one of the miRNAs whose sequences are shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.4, SEQ ID No.5, SEQ ID No.12, SEQ ID No.16, SEQ ID No.19, SEQ ID No.20, SEQ ID No.21, SEQ ID No.22, and SEQ ID No.

23.

3. The use according to claim 1 or 2, characterized in that: The miRNA uses exosomes as carriers, and the miRNA is encapsulated inside the exosomes.

4. The use according to claim 3, characterized in that: The exosomes or the exosomes encapsulating the miRNA are extracts derived from Pueraria lobata.

5. The use according to claim 4, characterized in that: The extract is derived from one or more of fresh kudzu root leaves, kudzu flower, kudzu root, kudzu vine, kudzu stem, kudzu processed products and kudzu decoction.

6. The use according to claim 3, characterized in that: The exosomes or the exosomes encapsulating the miRNA are functional exosomes with neuron targeting ligands modified on their surfaces.

7. The use according to claim 6, characterized in that: The targeting ligand is at least one of a small molecule, a polypeptide, an antibody, and a lipid.

8. A drug for treating Parkinson's disease, characterized in that: The drug contains miRNA, and the miRNA contains at least one of the miRNAs with sequences shown in SEQ ID No. 1 to SEQ ID No.

23.

9. A drug for treating Parkinson's disease, characterized in that: The drug comprises exosomes derived from Pueraria lobata, wherein miRNA is encapsulated inside the exosomes, and the miRNA comprises at least one of the miRNAs whose sequences are shown in SEQ ID No. 1 to SEQ ID No.

23.

10. The drug according to claim 9, characterized in that The exosomes are functional exosomes with neuron targeting ligands modified on the surface.